Small Randomized Trial Suggests a Benefit from Metformin as Adjunctive Therapy in Patients with Epidermal Growth Factor Receptor–Mutated Lung Adenocarcinoma
16 Sep, 2019 | 00:46h | UTCEffect of Metformin Plus Tyrosine Kinase Inhibitors Compared With Tyrosine Kinase Inhibitors Alone in Patients With Epidermal Growth Factor Receptor–Mutated Lung Adenocarcinoma: A Phase 2 Randomized Clinical Trial – JAMA Oncology (free for a limited period)
Commentary: Metformin Repurposed: Boosts Survival in TKI-Treated Lung Cancer – MedPage Today (free registration required)